GeneYouIn’s vision for GYI is based upon an optimal balance of clinical utility, patient empowerment, and cost-efficient, targeted genome analysis.
GeneYouIn (GYI) is a Canadian personalized medicine company. Our vision for GYI is based upon an optimal balance of clinical utility, patient empowerment, and cost-efficient, targeted genome analysis.
PillCheck (https://pillcheck.geneyouin.ca), our proprietary genome analytics and reporting platform, provides personalized, actionable recommendations for the selection of ~1/3 of all drugs dispensed in North America, and is primarily used for chronic care management. PillCheck is marketed as a drug response test, and it addresses variability in medication response to improve the benefit/risk ratio for patients, and to reduce exposure to unnecessary costs for payers. It represents $2B market opportunity in Canada.
PillCheck eliminates all barriers to genomic implementation and allows GYI’s channel partners – Health services companies, Benefits management companies, and Clinical Labs – to easily and rapidly add sophisticated genomic decision support to their product suites.
GYI already supplies PillCheck software to two CLIA-labs in United States, and established channel partnerships with Canadian firms: National Health Benefits Provider, Specialty Pharmacy Group and Integrated Health Clinics. FY2015 revenue: $410K.
PillCheck platform allows for multiple integration points for health services but it puts consumer/patient in control. Because PillCheck report contains evidence-based drug dosage recommendations and detailed references for 65+ meds, it brings necessary clarity to making important clinical decisions to all practitioners with whom patient chooses to interact – from his/her dentist to pharmacist to benefits case managers.
Our roadmap includes extension of PillCheck to other forms of genomic data, beyond PGx, such as nutrition, and application of PGx insights to evidence-based tiered drug formulary design.